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ABSTRACT:   The human leukocyte antigen (HLA) system plays an important role in the acceptance of renal graft. Long and better graft 
survival has been reported in patients with HLA-identical siblings and a nonreactive cytotoxicity assay (CDC). New methods of 
HLA-typing and anti-HLA antibody detection techniques such as flow cytometry, solid-phase immunoassays, or antigen bead 
assays have further improved the outcomes of renal transplant recipients. In the present review, the explicit details of these 
methodologies are discussed in detail.
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INTRODUCTION
The human leukocyte antigen (HLA) system provides a major bar-
rier to acceptance of renal transplants. In 1954, Joseph Murray et 
al. carried out the first successful renal transplantation between 
identical twins to eliminate problems related to an immune reac-
tion. (1). Longer survival has been reported in patients with grafts 
from HLA-identical siblings and a nonreactive cytotoxicity assay 
(CDC) compared to patients with grafts from randomly matched, 
deceased donors despite similar immunosuppressive treatment 
(2,3,4). Over the last two decades, new methods such as flow cy-
tometry, solid-phase immunoassays, or antigen bead assays such 
as Luminex have improved HLA-typing and anti-HLA antibody 
detection (5,6,7). A combined use of these newer techniques with 
CDC has improved immunological risk analysis (8,9).
HLA ANTIGENS
In 1952, Jean Dausset et al. first reported of the HLA system, i.e., 
the human major histocompatibility complex (MHC), after they 
noticed different kinds of alloantibodies against leukocytes in mul-
tiple blood transfusion recipients (10). The HLA system is present 
on chromosome 6p. Three class I HLA molecules, i.e., HLA-A, B, 
and C, are expressed on all nucleated cells, and they present in-
tracellular antigens. Six class II HLA molecules, i.e., HLA- DPA1, 
DPB1, DQA1, DQB1, DRA, and DRB1, are expressed only by an-
tigen-presenting cells and lymphocytes, and they present extra-
cellular antigens (11).  By presenting antigens to lymphocytes, 
the HLA molecules help in differentiating self from non-self. The 
magnitude of HLA mismatch at the A, B, and DR loci predicts the 
risk of graft rejection in potential recipients (12,13,14,15). When 
matching donors and recipients, one should avoid mismatching 
rather than matching each HLA antigens because of homozygous 
presentation of antigens e.g., HLA-A2.
The CDCXM was first introduced by Terasaki et al. in the 1960, 
and since then, it has become a standard technique to detect 
clinically significant donor- specific HLA antibodies (16). In 
CDCXM, isolated donor lymphocytes are separated into T and 
B cells and mixed with recipient serum. Subsequently, comple-
ment derived from rabbit serum is added. If donor-specific an-
tibodies bind to donor cells, the complement cascade will be 
activated via the classical pathway, leading to lymphocyte lysis 
(Figure. 1). The results are reported as the percentage of dead 
cells to live cells. A score of 2 is taken as the cutoff for a po-
sitive result (about 20% of cells undergo lysis), while the sco-
re of 8 defines complete cell lysis (Table. 1). The DCDXM is 
also used for semi-quantitative reaction strength assessment, 
by titrated crossmatch using serial serum dilutions, which co-
uld be beneficial in predicting negative crossmatch following 
desensitization. The sensitivity of basic CDCXM is not good 
and depends on the living donor cells and high antibodies ti-
tres (17,18). However, the sensitivity of basic CDCXM can be 
increased by adding antihuman globulin (AHG).
T-cell CDC: T lymphocytes express only class I HLA molecules, 
and a positive T-cell crossmatch incurs a very poor outcome. Patel 
et al. studied outcomes in 30 transplant recipients with a positive 
T-cell crossmatch, and they reported immediate graft loss in 24 
cases and early graft rejection, within 3 months, in the remaining 
patients. False positive reactions or lower immunogenicity of an-
tigens or antibodies could cause delayed rejection (19).
B-cell CDC: B lymphocytes express both class I and class II HLA 
molecules. B-cell crossmatching detects antibodies against class 
II HLA molecules. Positive results are not as decisive as in the 
case of T-cell crossmatching due to a higher rate of false positive 
results (50%) and time constraints in the case of deceased organ 
transplantation (20). Negative results are reassuring, i.e., even if 
the T-cell crossmatch is positive, this will be due to non-HLA 
antibodies alone (21,22). Most centres perform B-cell crossmat-
ching in living donor transplant assessment. In the case of posi-
tive results, the presence of DSA is better determined by more 
specific means such as the Luminex and flow crossmatch assays 
(23). However, B-cell crossmatching has many limitations as it 
detects only complement-activating isotypes of antibodies, requ-
ires a high degree of vital donor cells, and may show false positive 
results due to autoantibodies present in patients with autoimmu-
ne diseases (24,25,26).In the United Network of Sharing (UNOS) 
registry, 55% of CDCXM-positive transplant cases were FCXM-
-negative (27). The present case, with a positive CDCXM and a 
negative FCXM, could be explained by a false positive CDCXM, 
a false negative FCXM, or by IgM as the responsible antibody. 
SOLID PHASE ASSAY
Highly sensitive techniques such as enzyme-linked immunosorbent 
assay (ELISA) and Luminex were developed in order to address 
the limitation of the CDC procedure. Many laboratories have im-
plemented these methods in their protocol for all tissue typing (7).
ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
In ELISA, purified HLA class I or class II molecules are immobi-
lized on the surface of microparticles/beads. ELISA is highly sen-
sitive, and allows for antibody identification in 20%-30% of cases 
of AHG-augmented CDC-negative antibody screening. There are 
many ELISA-based flow cytometry methods, such as FlowPRA 
or LAT-M, but they are technically complex and expensive (31).
To confirm autoantibodies as the cause of false positive results, 
an auto-crossmatch was needed (28).
FLOW CYTOMETRY CROSSMATCH TECHNIQUE 
(FCXM)
In 1983, Garovoy et al. showed that the flow crossmatching tech-
nique facilitates transplantation (29). In FCXM, donor lymphocy-
tes and recipient serum are mixed in order to facilitate antibody 
binding. Subsequently, fluorescein-tagged anti-human globulin 
(AHG) is added to bind the attached DSA, which are detected by 
flow cytometry. Detection of fluorescently labelled detection anti-
bodies can identify isotype-specific antibodies. Further subtyping 
of IgG can also be done.
This further predicts the likelihood of complement activation as 
IgG4 antibodies do not activate complement in vivo (Figure. 2). 
Positive FCXM results are important when the CDCXM is nega-
tive, i.e., positive results are likely due to a non-complement fixing 
antibody, a non-HLA antibody, or a low-level antibody. In non-
-sensitized individuals, positive results are of no significance, whi-
le in sensitized individuals, they do suggest inferior graft survival. 
This can be explained by a higher rate of false positivity in non-
-sensitized individuals. Sometimes, the CDCXM is positive and a 
standard FCXM is negative, as in the present case scenario, which 
could be explained by IgM antibodies that are usually not detec-
ted on standard FCXM under anti-IgG tool because IgM antibo-
dies are not of pathological significance in transplant science (30).
To date, there are no clear recommendations regarding a routi-
ne use of this technique but some centres use it quite often in the 
context of donor-specific antibody results and CDCXM in order 
to predict an overall likelihood of immune complications.
Tab. I. CDCXM scoring system (Source: Terasaki et al. 2005).
SCORE DEAD CELL(%) DESCRIPTION/INTENSITY OF THE REACTION
1 < 10 Negative
2 10-20 Doubtful Positive
4 20-40 Weakly Positive
6 40-80 Positive
8 80-100 Strongly Positive
Tab. II. Methods To Reduce False Reactivity (Source: Authors Personal Collection).
METHOD MECHANISM COMMENTS
Heat Inactivation Aggregation of IgM Aggregates formed may bind non-specifically
Chemical 
Inactivation 
(Dithiothreitol and 
Dithioerythritol)
Reduction of 
disulfide bonds IgM
carcinogenic agents and may 
cause the loss of some IgG
Hypotonic Dialysis Filtration of IgM Small amounts of IgM left in filtrates
Amos (3-Wash) and 
Amos- modified 
(1-Wash)
Elimination of 
anticomplementary 
factors
Decreases false negative CDCXM
Prolonged 
incubation 
technique
Promotion of 
complement 
fixation
Decreases false negative CDCXM
Fig. 1.  Steps of CDC Crossmatch (Source: Authors own collection).
Fig. 2.  Steps of the FCXM (Source: Author’s own collection).
Donor specific HLA  antibodies in recipient serum: 
Antibody binds complement activated
Recipient Serum
May Contain donor-specific 
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complement activated
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labelled antibodies bind)
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Negative Crossmatch (no cell lysis)No Donor specific HLA antibodies 
present in recipient serum: No 
antibody binds
May Contain donor-specific HLA 
antibodies
Recipient SerumA
A
+
+
+
+
B
B
C
C
Donor Lymphocytes Complement
4342 WWW.PPCH.PL POL PRZEGL CHIR, 2018: 90 (1), 42-46DOI: 10.5604/01.3001.0011.5959
review articlereview article
Role of crossmatch testing when Luminex‑SAB is negative 
in renal transplantation
Kumar Jayant1, Isabella Reccia1, Bridson M Julie2, Ajay Sharma2, Ahmed Halawa2
1Department of Surgery and Cancer; Faculty of Medicine, Hammersmith Hospital, Imperial College London, UK 
2Faculty of Health and Sciences, Institute of Learning and Teaching, University of Liverpool, Liverpool L693BX, United Kingdom
Article history:  Received: 20.05.2016 Accepted: 20.07.2016  Published: 28.o2.2018
ABSTRACT:   The human leukocyte antigen (HLA) system plays an important role in the acceptance of renal graft. Long and better graft 
survival has been reported in patients with HLA-identical siblings and a nonreactive cytotoxicity assay (CDC). New methods of 
HLA-typing and anti-HLA antibody detection techniques such as flow cytometry, solid-phase immunoassays, or antigen bead 
assays have further improved the outcomes of renal transplant recipients. In the present review, the explicit details of these 
methodologies are discussed in detail.
KEYWORDS:  renal transplant, human leukocyte antigen, HLA-typing, anti-HLA antibody
INTRODUCTION
The human leukocyte antigen (HLA) system provides a major bar-
rier to acceptance of renal transplants. In 1954, Joseph Murray et 
al. carried out the first successful renal transplantation between 
identical twins to eliminate problems related to an immune reac-
tion. (1). Longer survival has been reported in patients with grafts 
from HLA-identical siblings and a nonreactive cytotoxicity assay 
(CDC) compared to patients with grafts from randomly matched, 
deceased donors despite similar immunosuppressive treatment 
(2,3,4). Over the last two decades, new methods such as flow cy-
tometry, solid-phase immunoassays, or antigen bead assays such 
as Luminex have improved HLA-typing and anti-HLA antibody 
detection (5,6,7). A combined use of these newer techniques with 
CDC has improved immunological risk analysis (8,9).
HLA ANTIGENS
In 1952, Jean Dausset et al. first reported of the HLA system, i.e., 
the human major histocompatibility complex (MHC), after they 
noticed different kinds of alloantibodies against leukocytes in mul-
tiple blood transfusion recipients (10). The HLA system is present 
on chromosome 6p. Three class I HLA molecules, i.e., HLA-A, B, 
and C, are expressed on all nucleated cells, and they present in-
tracellular antigens. Six class II HLA molecules, i.e., HLA- DPA1, 
DPB1, DQA1, DQB1, DRA, and DRB1, are expressed only by an-
tigen-presenting cells and lymphocytes, and they present extra-
cellular antigens (11).  By presenting antigens to lymphocytes, 
the HLA molecules help in differentiating self from non-self. The 
magnitude of HLA mismatch at the A, B, and DR loci predicts the 
risk of graft rejection in potential recipients (12,13,14,15). When 
matching donors and recipients, one should avoid mismatching 
rather than matching each HLA antigens because of homozygous 
presentation of antigens e.g., HLA-A2.
The CDCXM was first introduced by Terasaki et al. in the 1960, 
and since then, it has become a standard technique to detect 
clinically significant donor- specific HLA antibodies (16). In 
CDCXM, isolated donor lymphocytes are separated into T and 
B cells and mixed with recipient serum. Subsequently, comple-
ment derived from rabbit serum is added. If donor-specific an-
tibodies bind to donor cells, the complement cascade will be 
activated via the classical pathway, leading to lymphocyte lysis 
(Figure. 1). The results are reported as the percentage of dead 
cells to live cells. A score of 2 is taken as the cutoff for a po-
sitive result (about 20% of cells undergo lysis), while the sco-
re of 8 defines complete cell lysis (Table. 1). The DCDXM is 
also used for semi-quantitative reaction strength assessment, 
by titrated crossmatch using serial serum dilutions, which co-
uld be beneficial in predicting negative crossmatch following 
desensitization. The sensitivity of basic CDCXM is not good 
and depends on the living donor cells and high antibodies ti-
tres (17,18). However, the sensitivity of basic CDCXM can be 
increased by adding antihuman globulin (AHG).
T-cell CDC: T lymphocytes express only class I HLA molecules, 
and a positive T-cell crossmatch incurs a very poor outcome. Patel 
et al. studied outcomes in 30 transplant recipients with a positive 
T-cell crossmatch, and they reported immediate graft loss in 24 
cases and early graft rejection, within 3 months, in the remaining 
patients. False positive reactions or lower immunogenicity of an-
tigens or antibodies could cause delayed rejection (19).
B-cell CDC: B lymphocytes express both class I and class II HLA 
molecules. B-cell crossmatching detects antibodies against class 
II HLA molecules. Positive results are not as decisive as in the 
case of T-cell crossmatching due to a higher rate of false positive 
results (50%) and time constraints in the case of deceased organ 
transplantation (20). Negative results are reassuring, i.e., even if 
the T-cell crossmatch is positive, this will be due to non-HLA 
antibodies alone (21,22). Most centres perform B-cell crossmat-
ching in living donor transplant assessment. In the case of posi-
tive results, the presence of DSA is better determined by more 
specific means such as the Luminex and flow crossmatch assays 
(23). However, B-cell crossmatching has many limitations as it 
detects only complement-activating isotypes of antibodies, requ-
ires a high degree of vital donor cells, and may show false positive 
results due to autoantibodies present in patients with autoimmu-
ne diseases (24,25,26).In the United Network of Sharing (UNOS) 
registry, 55% of CDCXM-positive transplant cases were FCXM-
-negative (27). The present case, with a positive CDCXM and a 
negative FCXM, could be explained by a false positive CDCXM, 
a false negative FCXM, or by IgM as the responsible antibody. 
SOLID PHASE ASSAY
Highly sensitive techniques such as enzyme-linked immunosorbent 
assay (ELISA) and Luminex were developed in order to address 
the limitation of the CDC procedure. Many laboratories have im-
plemented these methods in their protocol for all tissue typing (7).
ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
In ELISA, purified HLA class I or class II molecules are immobi-
lized on the surface of microparticles/beads. ELISA is highly sen-
sitive, and allows for antibody identification in 20%-30% of cases 
of AHG-augmented CDC-negative antibody screening. There are 
many ELISA-based flow cytometry methods, such as FlowPRA 
or LAT-M, but they are technically complex and expensive (31).
To confirm autoantibodies as the cause of false positive results, 
an auto-crossmatch was needed (28).
FLOW CYTOMETRY CROSSMATCH TECHNIQUE 
(FCXM)
In 1983, Garovoy et al. showed that the flow crossmatching tech-
nique facilitates transplantation (29). In FCXM, donor lymphocy-
tes and recipient serum are mixed in order to facilitate antibody 
binding. Subsequently, fluorescein-tagged anti-human globulin 
(AHG) is added to bind the attached DSA, which are detected by 
flow cytometry. Detection of fluorescently labelled detection anti-
bodies can identify isotype-specific antibodies. Further subtyping 
of IgG can also be done.
This further predicts the likelihood of complement activation as 
IgG4 antibodies do not activate complement in vivo (Figure. 2). 
Positive FCXM results are important when the CDCXM is nega-
tive, i.e., positive results are likely due to a non-complement fixing 
antibody, a non-HLA antibody, or a low-level antibody. In non-
-sensitized individuals, positive results are of no significance, whi-
le in sensitized individuals, they do suggest inferior graft survival. 
This can be explained by a higher rate of false positivity in non-
-sensitized individuals. Sometimes, the CDCXM is positive and a 
standard FCXM is negative, as in the present case scenario, which 
could be explained by IgM antibodies that are usually not detec-
ted on standard FCXM under anti-IgG tool because IgM antibo-
dies are not of pathological significance in transplant science (30).
To date, there are no clear recommendations regarding a routi-
ne use of this technique but some centres use it quite often in the 
context of donor-specific antibody results and CDCXM in order 
to predict an overall likelihood of immune complications.
Tab. I. CDCXM scoring system (Source: Terasaki et al. 2005).
SCORE DEAD CELL(%) DESCRIPTION/INTENSITY OF THE REACTION
1 < 10 Negative
2 10-20 Doubtful Positive
4 20-40 Weakly Positive
6 40-80 Positive
8 80-100 Strongly Positive
Tab. II. Methods To Reduce False Reactivity (Source: Authors Personal Collection).
METHOD MECHANISM COMMENTS
Heat Inactivation Aggregation of IgM Aggregates formed may bind non-specifically
Chemical 
Inactivation 
(Dithiothreitol and 
Dithioerythritol)
Reduction of 
disulfide bonds IgM
carcinogenic agents and may 
cause the loss of some IgG
Hypotonic Dialysis Filtration of IgM Small amounts of IgM left in filtrates
Amos (3-Wash) and 
Amos- modified 
(1-Wash)
Elimination of 
anticomplementary 
factors
Decreases false negative CDCXM
Prolonged 
incubation 
technique
Promotion of 
complement 
fixation
Decreases false negative CDCXM
Fig. 1.  Steps of CDC Crossmatch (Source: Authors own collection).
Fig. 2.  Steps of the FCXM (Source: Author’s own collection).
Donor specific HLA  antibodies in recipient serum: 
Antibody binds complement activated
Recipient Serum
May Contain donor-specific 
HLA antibodies
No Donor specific HLA antibodies present 
in recipient: No antibody binds
Donor specific HLA  antibodies in 
recipient serum: Antibody binds 
complement activated
Negative Crossmatch (no Fluorescent 
labelled antibodies bind)
Positive Crossmatch 
(Fluorescent Labelled 
antibodies bind)
Donor 
Lymphocytes
Fluorescent labelled 
antibodies against human 
IgG
Positive Crossmatch  (cell lysis)
Negative Crossmatch (no cell lysis)No Donor specific HLA antibodies 
present in recipient serum: No 
antibody binds
May Contain donor-specific HLA 
antibodies
Recipient SerumA
A
+
+
+
+
B
B
C
C
Donor Lymphocytes Complement
WWW.PPCH.PL 4544 POL PRZEGL CHIR, 2018: 90 (1), 42-46
review articlereview article
which helps in antibody titre correlation. The most commonly used 
MESF cutoff is 1,000 although studies have shown that MESF valu-
es well above this level can be associated with a negative CDCXM. 
Even if there is no reaction on crossmatching, DSA presence on 
Luminex may have a prognostic significance for the transplanted 
kidney (37). Studies have reported that recipients with donor-spe-
cific anti-HLA antibodies have worse graft survival compared to 
recipients with non-donor specific anti-HLA antibodies, which is 
still worse than no DSA (38,39). The main advantage of the Lumi-
nex technique is its ability to detect specific antibodies, which eli-
minates the risk of false positivity. However, the Luminex techni-
que has some limitations as well; for instance, incomplete or varied 
antigen representation on beads or presence of IgM antibodies can 
affect results (40,41). False negative results are also reported in the 
case of high HLA antibody titres due to the prozone effect or IgM 
antibodies, which hinders anti-HLA antibody binding to beads, 
or due to epitope sharing between different antigen beads (42).
PANEL REACTIVE ANTIBODIES (PRA)
In an analysis of panel reactive antibodies (PRA), recipient serum 
is mixed with a panel of lymphocytes representing a potential 
donor HLA makeup. The result is reported as the percentage of 
PRA reactions (%PRA). In non-sensitized candidates, it is 0, and 
if candidate’s serum reacts in 80 out of 100 cases, it is 80%. Cli-
nically, this result is interpreted as a high likelihood of rejection, 
i.e., 8 out of 10 times. Technological advancement has improved 
the determination of antibody specificity. Maintaining records of 
antigens increases the efficiency of organ allocation by screening 
off incompatible donors; otherwise, recipients would be at a high 
risk of hyperacute rejection. The frequency of unacceptable anti-
gens in the national donor pool can be used for determination of 
calculated panel reactive antibodies (CPRA), i.e., the likelihood 
of incompatibility, by using a computer-based algorithm (43,44).
CONCLUSION
We evaluated the effect of DSA positivity in the case of a negative 
CDCXM. However, there are few report regarding the impact of 
DSA negativity in the case of a positive CDCMX. In 2011, Amico 
et al. reported an excellent graft outcome with a negative virtual 
crossmatch (39). Few anecdotal reports exist in which a desensiti-
zation protocol was used for such cases. Furthermore, even post-
-desensitization, there was no change in tissue matching status; 
thus, it was not needed. However, either omission of a positive CDC 
crossmatch or choosing desensitization is the clinician’s discretion.
LUMINEX- SAB (SINGLE ANTIGEN BEAD)
Luminex technique uses antigen coated beads (microspheres) with 
either multiple HLA antigens for screening purposes or a single 
HLA antigen in order to increase specificity (32). This technique 
has been used in many ways as in determining the specific anti-
-HLA antibodies or virtual crossmatching. These coated beads 
with unique fluorochrome are mixed with recipient serum. When 
anti-HLA antibodies present in serum bind to the beads and are 
detected by an isotype- specific (e.g. IgG) detection antibody via 
flow cytometry they fluoresce. (Figure. 3) Antibodies are defined 
against HLA class I and II antigens (33). This virtual crossmatch is 
used as the reference for comparison of the anti- HLA antibodies 
of the recipient, with the HLA of the donor. Amajor advantage of 
the Luminex-SAB is that, in the case of negative results, one co-
uld omit CDCXM testing, which reduces cold ischemia time and 
the need of immunosuppression. False positive results are among 
the major limitation of the Luminex-SAB; they are due to techni-
cal reasons as they do not detect all HLA-directed antibodies but 
only those against the most common HLA molecules (34,35,36).
The results are reported as molecules of equivalent soluble fluore-
scence (MESF) and can be graded into weak, moderate, or strong, 
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which helps in antibody titre correlation. The most commonly used 
MESF cutoff is 1,000 although studies have shown that MESF valu-
es well above this level can be associated with a negative CDCXM. 
Even if there is no reaction on crossmatching, DSA presence on 
Luminex may have a prognostic significance for the transplanted 
kidney (37). Studies have reported that recipients with donor-spe-
cific anti-HLA antibodies have worse graft survival compared to 
recipients with non-donor specific anti-HLA antibodies, which is 
still worse than no DSA (38,39). The main advantage of the Lumi-
nex technique is its ability to detect specific antibodies, which eli-
minates the risk of false positivity. However, the Luminex techni-
que has some limitations as well; for instance, incomplete or varied 
antigen representation on beads or presence of IgM antibodies can 
affect results (40,41). False negative results are also reported in the 
case of high HLA antibody titres due to the prozone effect or IgM 
antibodies, which hinders anti-HLA antibody binding to beads, 
or due to epitope sharing between different antigen beads (42).
PANEL REACTIVE ANTIBODIES (PRA)
In an analysis of panel reactive antibodies (PRA), recipient serum 
is mixed with a panel of lymphocytes representing a potential 
donor HLA makeup. The result is reported as the percentage of 
PRA reactions (%PRA). In non-sensitized candidates, it is 0, and 
if candidate’s serum reacts in 80 out of 100 cases, it is 80%. Cli-
nically, this result is interpreted as a high likelihood of rejection, 
i.e., 8 out of 10 times. Technological advancement has improved 
the determination of antibody specificity. Maintaining records of 
antigens increases the efficiency of organ allocation by screening 
off incompatible donors; otherwise, recipients would be at a high 
risk of hyperacute rejection. The frequency of unacceptable anti-
gens in the national donor pool can be used for determination of 
calculated panel reactive antibodies (CPRA), i.e., the likelihood 
of incompatibility, by using a computer-based algorithm (43,44).
CONCLUSION
We evaluated the effect of DSA positivity in the case of a negative 
CDCXM. However, there are few report regarding the impact of 
DSA negativity in the case of a positive CDCMX. In 2011, Amico 
et al. reported an excellent graft outcome with a negative virtual 
crossmatch (39). Few anecdotal reports exist in which a desensiti-
zation protocol was used for such cases. Furthermore, even post-
-desensitization, there was no change in tissue matching status; 
thus, it was not needed. However, either omission of a positive CDC 
crossmatch or choosing desensitization is the clinician’s discretion.
LUMINEX- SAB (SINGLE ANTIGEN BEAD)
Luminex technique uses antigen coated beads (microspheres) with 
either multiple HLA antigens for screening purposes or a single 
HLA antigen in order to increase specificity (32). This technique 
has been used in many ways as in determining the specific anti-
-HLA antibodies or virtual crossmatching. These coated beads 
with unique fluorochrome are mixed with recipient serum. When 
anti-HLA antibodies present in serum bind to the beads and are 
detected by an isotype- specific (e.g. IgG) detection antibody via 
flow cytometry they fluoresce. (Figure. 3) Antibodies are defined 
against HLA class I and II antigens (33). This virtual crossmatch is 
used as the reference for comparison of the anti- HLA antibodies 
of the recipient, with the HLA of the donor. Amajor advantage of 
the Luminex-SAB is that, in the case of negative results, one co-
uld omit CDCXM testing, which reduces cold ischemia time and 
the need of immunosuppression. False positive results are among 
the major limitation of the Luminex-SAB; they are due to techni-
cal reasons as they do not detect all HLA-directed antibodies but 
only those against the most common HLA molecules (34,35,36).
The results are reported as molecules of equivalent soluble fluore-
scence (MESF) and can be graded into weak, moderate, or strong, 
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ABSTRACT:   Overtreatment means treatment that goes beyond current standards, and patients with any disease can be overtreated. Over-
treatment is also given to patients with cancer, including those who need surgery. Overtreatment is closely related to the 
problem of overdiagnosis.    
  In patients with cancer, unnecessary surgery may cause complications and generates unnecessary costs. The size of the prob-
lem of unnecessary surgery in patients with cancer can best be shown among patients with the most common cancers, which 
dedicated screening programs. Breast cancer patients, particularly those with pre-invasive types of the tumor, who typically 
have ductal carcinoma in situ (80%), are likely to undergo unnecessary surgery. We describe the most common clinical prob-
lems caused by overtreating patients with ductal carcinoma in situ. 
KEYWORDS:  overtreatment, overdiagnosis, surgical treatment, breast cancer, ductal carcinoma in situ
The problem mentioned in the title of the study that means excessive 
treatment (treatment beyond therapeutic standards) may concern 
any form of healthcare. This phenomenon also occurs in oncology 
including patients with malignancies requiring surgical treatment. 
Overtreatment is directly connected with overdiagnosis. The se-
cond term means diagnosing a disease which would not result 
in symptoms (including especially patient’s death) if it remained 
undetected. Thus, according to the definition of „overdiagnosis”, 
„overtreatment” includes all the cases of treatment administered 
as a result of overdiagnosis.  
Except for an important economic aspect (generation of signifi-
cant expenses), a potentially avoidable surgery also results in con-
ditions that are caused by adverse effects of operations. Therefore, 
the problem of overtreatment is analyzed more and more often [1].
The scale of this problem can be presented in those cancer patients 
who underwent surgery, by analyzing the morbidity of malignant 
neoplasms that are included in screening programs. It mostly re-
fers to breast cancer patients and especially those with preinva-
sive carcinomas. Ductal carcinoma in situ (DCIS) accounts for 
around 80% thereof [2].
CAUSES AND SCALE OF OVERTREATMENT 
Introduction of National Breast Cancer Early Detection Programs 
is believed to be the most important cause of overdiagnosis (and 
therefore also overtreatment) of DCIS. Before these programs 
were implemented, DCIS constituted 3-5% of all breast cancer 
cases. Popularization of screening mammography increased the 
percentage to 20-30% of all detected types of breast cancer (Eu-
rope, North America) [2-4]. 
An increase in overall morbidity of breast cancer also contributed 
to the rise in the number of DCIS cases. According to the epide-
miological data, between 1988 and 2010, it was observed that in 
the United Kingdom the standardized morbidity index of ductal 
cancer in situ significantly increased from 3.6 to 16.2 per 100 000. 
In invasive cancer, the difference was not so pronounced (90.9/100 
000 vs. 126.2/100 000) [5].  In the same time period, a similar ten-
dency in DCIS morbidity was observed also in Holland (increase 
from 4.9 to 22.3/100 000) [6] and Germany (the incidence of DCIS 
increased 7 times) [7].  
More frequent detection, especially of tumors of small size, was 
also facilitated by technological progress in the parameters of dia-
gnostic tests (introduction of digital mammography and devices 
with tomosynthesis mode, and popularization of magnetic reso-
nance mammography) [8].
Ductal carcinoma in situ is a disease characterized by different 
grades [9]. According to the observations of the authors from Ha-
rvard Medical School, lesion of DCIS may develop in two different 
ways. Progress of the disease may lead to occurrence of high-risk 
DCIS (extensive pure ductal carcinoma in situ). It requires simi-
lar therapeutic approach as invasive breast cancer. Low-risk DCIS 
(indolent disease, low-grade DCIS) is the second option [10]. This 
type is only rarely a source of invasive high-grade cancer (G3). In-
vasive G3 cancer in a patient previously diagnosed with low-risk 
DCIS may be considered an entirely new, primary malignant bre-
ast neoplasm [11]. These conclusions are also confirmed by other 
authors [12, 13].
Among the above mentioned causes, administration of treatment 
in patients with low-risk ductal carcinomas is considered overtre-
atment. It mostly concerns surgical procedures of the axillary fossa 
(sentinel node resection, lymphadenectomy) and overly high rate 
of mastectomy [14]. Therefore, according to some publications, 
estimated percentage of overtreatment may be as high a 52% of 
all DCIS cases [15-18]. 
However, according to many authors, overtreatment should be 
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